Press coverage about Cellular Biomedicine Group (NASDAQ:CBMG) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.7894004200265 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Cellular Biomedicine Group (NASDAQ CBMG) traded up $1.65 during trading on Monday, reaching $19.65. 107,969 shares of the company’s stock traded hands, compared to its average volume of 139,867. The company has a market capitalization of $275.30, a PE ratio of -11.42 and a beta of 2.59. Cellular Biomedicine Group has a 12-month low of $5.05 and a 12-month high of $22.40.
Cellular Biomedicine Group (NASDAQ:CBMG) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.43) earnings per share for the quarter. Cellular Biomedicine Group had a negative return on equity of 42.56% and a negative net margin of 7,579.14%.
In other news, CEO Tony Liu purchased 29,167 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was acquired at an average price of $12.00 per share, with a total value of $350,004.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Yihong Yao purchased 4,167 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was purchased at an average cost of $12.00 per share, with a total value of $50,004.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 41,667 shares of company stock worth $500,004. Company insiders own 8.20% of the company’s stock.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Cellular Biomedicine Group (CBMG) Stock Price” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-cellular-biomedicine-group-cbmg-stock-price/1817894.html.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.